Treg Fragility: A Prerequisite for Effective Antitumor Immunity?

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Immunotherapy, including checkpoint blockade, has improved cancer treatment response rates.
• However, a significant portion of patients remain unresponsive to immunotherapy.
• Regulatory T cells (Tregs) within the tumor microenvironment (TME) are key suppressors of antitumor immunity.

Purpose of the Study:

• To review the impact of Tregs on the TME and their implications for cancer immunotherapy responsiveness.
• To explore the concept of Treg "fragility" as a predictor of immunotherapy outcomes.
• To propose targeted strategies to modulate Treg function within the TME.

Main Methods:

• Literature review focusing on Treg function, TME characteristics, and immunotherapy resistance.
• Analysis of Treg-TME interactions and their influence on immune responses.
• Exploration of molecular mechanisms underlying Treg instability and fragility.

Main Results:

• The TME presents a hostile environment for immune cells, with Tregs playing a critical role in immune suppression.
• Systemic Treg depletion is undesirable due to potential autoimmunity.
• Intratumoral Treg "fragility," induced by factors like Interferon-γ (IFNγ), leads to reduced suppressive activity and increased IFNγ production without losing Foxp3 expression.

Conclusions:

• Treg function within the TME is a significant barrier to effective cancer immunotherapy.
• Modulating Treg function specifically within the TME offers a targeted approach to enhance antitumor immunity.
• The degree of intratumoral Treg fragility following immunotherapy may serve as a predictive biomarker for patient responsiveness.